Inactive Instrument

Company POIT BIOP

Equities

RACA

US7305411099

Business Summary

POINT Biopharma Global Inc. is a radiopharmaceutical company. The Company is engaged in building a platform for the clinical development and commercialization of radioligands that fight cancer. The Company is focused on transforming precision medicine by combining a portfolio of radiopharmaceutical assets, a seasoned management team, a pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like actinium-225 (Ac) and lutetium-177 (Lu). Its pipeline consists of late-stage programs in prostate cancer (PNT2002) and neuroendocrine tumors (PNT2003). Its Lu-PNT2002 is a late-stage prostate-specific membrane antigen (PSMA) targeted radioligand therapy. Its Lu-PNT2003 is a late-stage somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors. Its PNT2004 is a fibroblast activation protein-a (FAP) targeting program being developed for use in multiple tumor types.

Number of employees: 129

Managers

Managers TitleAgeSince
President 59 Dec. 26
Director/Board Member - Dec. 26

Members of the board

Members of the board TitleAgeSince
Director/Board Member - Dec. 26
Director/Board Member - Dec. 26
Director/Board Member - Dec. 26

Company contact information

POINT Biopharma Global, Inc.

4850 West 78th Street

46268, Indianapolis

+

http://www.pointbiopharma.com
address POIT BIOP(RACA)

Sector

This company's sector is not yet available